美国活产儿中的不孕不育治疗与紫绀型先天性心脏缺陷:一项当代队列研究的结果
不孕不育治疗者CCHD患病率为1.2/1000活产儿,自然受孕者为0.5/1000活产儿,调整后OR为2.06(95%CI 1.82-2.33)。
要点
- 不孕不育治疗者CCHD患病率1.2/1000活产儿,自然受孕者0.5/1000活产儿。
- 相比自然受孕,任何不孕不育治疗与CCHD odds升高相关(OR 2.06,95%CI 1.82-2.33)。
- 辅助生殖技术与其他不孕不育治疗间关联无显著差异(OR 1.04,95%CI 0.82-1.33,P=0.712)。
核心结论
- 在这项单胎活产儿的人群研究中,不孕不育治疗(辅助生殖技术或非辅助生殖技术)与活产儿CCHD患病率升高相关,该关联不能作因果解读。
研究设计与样本
- 不孕不育治疗使用和CCHD信息来自出生证明健康与医疗信息部分,由医务人员查阅病历后填写。
- 采用逻辑回归模型估计OR和95%CI,并进行熵平衡加权分析和概率偏倚分析。
主要发现
- 研究期间不孕不育治疗后的活产比例从1.9%(27116例)上升至3.1%(43510例)。
- 共5287例CCHD,总患病率为0.6/1000活产儿。
- 不孕不育治疗使用者CCHD患病率为1.2/1000活产儿(辅助生殖技术1.1/1000,非辅助生殖技术1.3/1000),自然受孕者为0.5/1000活产儿。
- 调整母方和父方年龄、种族和民族、教育、母亲出生地、婚姻状况、支付来源、吸烟状况及孕前BMI、高血压和糖尿病后,相比自然受孕,任何不孕不育治疗与CCHD odds升高相关(OR 2.06,95%CI 1.82-2.33),辅助生殖技术OR 2.02(95%CI 1.73-2.36),其他不孕不育治疗OR 2.12(95%CI 1.74-2.33)。
- 关联在不孕不育治疗类型间无差异(辅助生殖技术与其他不孕不育治疗比较OR 1.04,95%CI 0.82-1.33,P=0.712),且对暴露和结局错分偏倚及残余混杂稳健。
临床怎么用
- 作者认为这些发现有助于对辅助生殖技术或其他不孕不育治疗受孕的妊娠进行孕前咨询和产前保健。
- 作者认为这些发现支持当前一些推荐,即不孕不育治疗后的妊娠应接受胎儿超声心动图筛查。
局限性
- 研究结果仅限活产儿。
- 无法检查终止妊娠数据,但既往旨在考虑该问题的研究不支持受孕方式导致的差异性终止妊娠。
- 不孕不育治疗使用为自我报告,可能导致选择偏倚以及不孕不育治疗和CCHD的错分。
- 缺乏不孕不育病因(母方、父方或双方因素)、特定辅助生殖技术和其他不孕不育治疗类型以及CCHD亚型的信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is there an elevated risk of cyanotic congenital heart defects (CCHD) among livebirths following infertility treatments? SUMMARY ANSWER: In this population-based study of single livebirths, infertility treatment (either ART or non-ART) was associated with a higher prevalence of CCHD among livebirths. WHAT IS KNOWN ALREADY: The use of infertility treatment has been on the rise over the past few decades. However, there are limited studies assessing the risk of major cardiac defects following infertility treatments. STUDY DESIGN, SIZE, DURATION: A retrospective cohort study of livebirth data from the National Vital Statistics System (NVSS) was conducted, comprising of 9.6 million singleton livebirths among first-time mothers aged 15-49 years from 2016 to 2022. PARTICIPANTS/MATERIALS, SETTING, METHODS: Information on infertility treatment use and CCHD was obtained from the health and medical information section of birth certificates, which was completed by healthcare staff after reviewing medical records. Logistic regression models were used to estimate odds ratios (OR) and 95% CI. Entropy balancing weighting analysis and probabilistic bias analysis were also performed. MAIN RESULTS AND THE ROLE OF CHANCE: The proportion of births following infertility treatment increased from 1.9% (27 116) to 3.1% (43 510) during the study period. Overall, there were 5287 cases of CCHD resulting in a prevalence of 0.6 per 1000 livebirths. The prevalence was 1.2 per 1000 live births among infertility treatment users (ART: 1.1 per 1000 livebirths; non-ART: 1.3 per 1000 livebirths) while that for naturally conceived births was 0.5 per 1000 livebirths. Compared to naturally conceived births, the use of any infertility treatment (OR: 2.06, 95% CI: 1.82-2.33), either ART (OR: 2.02, 95% CI: 1.73-2.36) or other infertility treatments (OR: 2.12, 95% CI: 1.74-2.33), was associated with higher odds of CCHD after adjusting for maternal and paternal age, race and ethnicity, and education, as well as maternal nativity, marital status, source of payment, smoking status, and pre-pregnancy measures of BMI, hypertension and diabetes. This association did not differ by the type of infertility treatment (ART versus other infertility treatments) (OR: 1.04, 95% CI: 0.82-1.33, P = 0.712), and was robust to the presence of exposure and outcome misclassification bias and residual confounding. LIMITATIONS, REASONS FOR CAUTION: The findings are only limited to livebirths. We did not have the capacity to examine termination data, but differential termination by mode of conception has not been supported by previous studies designed to consider it. Infertility treatment use was self-reported, leading to the potential for selection bias and misclassification for infertility treatment and CCHD. However, the association persisted when systematic bias as well as exposure and outcome misclassification bias were accounted for in the analyses. Information on the underlying etiology of infertility relating to either maternal, paternal, or both factors, data on specific types of ART and other infertility treatments, as well as information on subtypes of CCHD, were all not available. WIDER IMPLICATIONS OF THE FINDINGS: In light of the increasing trend in the use of infertility treatment in the USA, and elsewhere, the finding of the current study holds significant importance for the clinical and public health of reproductive-aged individuals. The data show that the use of infertility treatment may expose offspring to elevated odds of severe congenital heart defects such as CCHD studied here. These findings cannot be interpreted causally. While our findings can assist in preconception counseling and prenatal care for pregnancies conceived by either ART or other infertility treatments, they also support some current recommendations that pregnancies resulting from infertility treatments undergo fetal echocardiography screening. STUDY FUNDING/COMPETING INTEREST(S): No funding was sought for the study. The authors declare that they have no conflict of interest. TRIAL REGISTRAION NUMBER: N/A.
引用
- Appiah D, Sang J, Olayemi OE, et al. Infertility treatments and cyanotic congenital heart defects among livebirths in the USA: findings from a contemporary cohort. Hum Reprod. 2024. PMID: 39008825. doi:10.1093/humrep/deae161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。